Trial
NCT01009346
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Novartis Pharmaceuticals
Condition
Head and Neck Cancer
Intervention
RAD001
Why stopped
Toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-07-17